Analysis of curative effect of Endu combined with cisplatin intrapleural injection on malignant pleural effusion of non-small cell lung cancer
10.3969/j.issn.1005-1678.2017.05.090
- VernacularTitle:恩度联合顺铂胸腔内注射治疗非小细胞肺癌恶性胸腔积液的疗效分析
- Author:
Haiqin WANG
;
Dakui CAO
;
Yangwei YAO
- Keywords:
Endu;
cisplatin;
non-small cell lung cancer;
malignant pleural effusion;
clinical efficacy
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(5):272-274
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize the clinical efficacy of Endu combined with intrapleural injection of cisplatin in the treatment of malignant pleural effusion of non-small cell lung cancer.Methods80 patients with malignant pleural effusion were selected from January 2014 to December 2015.The patients were randomly divided into observation group and control group (n=40).The control group was given Endu(40mg/time, 1 time/week) combined with cisplatin (40mg/time, 1 time/week) intraperitoneal injection treatment, the treatment group was given Endu intraperitoneal injection therapy, After 4 weeks of treatment, the clinical efficacy and adverse reactions were observed.ResultsThe clinical efficacy of the observation group was significantly higher than that of the control group (50.00%).The difference was statistically significant (P<0.05).The incidence of adverse reactions in the observation group was 15.00% higher than that in the control group, but the difference was not significant.The improvement rate of life quality in the observation group was significantly higher than that in the control group (52.50%).The difference between the two groups was statistically significant (P<0.05).ConclusionThe clinical efficacy of Endu combined with intrapleural injection of cisplatin in the treatment of malignant pleural effusion of non-small cell lung cancer is superior to that of simple analgesia, which can significantly improve the clinical symptoms and quality of life.It is worthy to be popularized in clinical practice.
